A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of DZD2269 Oral Tablet Following Single and Multiple Ascending Dose Administration to Healthy Adult Participants
Latest Information Update: 04 Jul 2022
At a glance
- Drugs DZD 2269 (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions
- Acronyms PAN-GU 2
- Sponsors Dizal Pharmaceutical
- 28 Jun 2022 Status changed from recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 27 May 2022 Results published in Dizal Pharmaceutical Media Release.